ERBB2 and gastric cancer: The ToGA trial was a pivotal clinical trial that demonstrated a significant overall survival (OS) improvement in patients with HER2-positive unresectable or recurrent GC who received trastuzumab in combination with standard chemotherapy (cisplatin and 5-FU) [15].